Prolonged Cholestatic Jaundice Associated With Flurbiprofen

Doğan, Serkan; Celıkbılek, Mehmet; Demirkan, Kutay; Yılmaz, Semih; Denız, Kemal; Gürsoy, Şebnem; Yücesoy, Mehmet

doi:10.1177/0897190013515706

Cited by 3 publications

(2 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, vanishing bile duct syndrome, which is considered a serious variant of liver damage characterised by bile duct injury and ductopenia has been linked to ibuprofen use [24]. Case reports of celecoxib-and sulindac-induced cholestasis have been published, notably, presenting as fulminant liver failure [28,29].…”

Section: Nsaidsmentioning

confidence: 99%

Drug-induced cholestasis: causative agents and challenges in diagnosis and management

Pinazo-Bandera,

Toro-Ortiz,

Andrade

et al. 2023

Explor Dig Dis

View full text Add to dashboard Cite

Drug-induced liver injury (DILI) is an adverse reaction to drugs and other xenobiotics that can have serious consequences and jeopardise progress in pharmacological therapy. While DILI is predominantly hepatocellular, a non-negligible percentage of patients who present with cholestatic damage. Mixed damage is typically lumped together with cholestatic damage in the literature. Drug-induced cholestasis is often caused by the use of some non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics (i.e., amoxicillin-clavulanic acid), statins, and anabolic agents, among others. Drug-associated cholestasis tends to have a more chronic course and mostly affects older population. There is also a genetic predisposition to toxic cholestasis caused by some drugs (amoxicillin-clavulanic acid, statins, etc.). Recently, anatomical alterations of the biliary tract induced by drugs (especially immunotherapy drugs) have been described. Bile duct injury is one of the histopathological findings that have prognostic significance in DILI. A correct differential diagnosis with other causes of cholestasis is mandatory to reach an accurate diagnosis. Ursodexycholic acid, corticosteroids, and replacement therapies have been used as a therapeutic arsenal, although more evidence is needed to establish them as a routine therapeutic management in clinical practice. The breakthrough and validation of biomarkers of cholestasis and bile duct injury is an urgent need for drug development and post-marketing phase.

show abstract

Section: Nsaidsmentioning

confidence: 99%

Drug-induced cholestasis: causative agents and challenges in diagnosis and management

Pinazo-Bandera,

Toro-Ortiz,

Andrade

et al. 2023

Explor Dig Dis

View full text Add to dashboard Cite

show abstract

“…In combination, APAP and IBP have the highest incidence of all NSAID overdose with a short latency period of hepatocellular injury (Gummin et al, 2020; Zoubek et al, 2020). FLB overdose is associated with prolonged cholestatic jaundice and drug‐induced liver injury (Dağ et al, 2014; Dogan et al, 2014). The history of drug exposure of many emergency patients is often not easily determined, and intoxication from multiple drugs may be present.…”

Section: Introductionmentioning

confidence: 99%

Rapid identification of potential nonsteroidal anti‐inflammatory drug overdose–induced liver toxicity and prediction of follow‐up exposure: Integrating bioanalytical and population pharmacokinetic assay

Zhou,

Zhao,

Wang

et al. 2024

Biomedical Chromatography

View full text Add to dashboard Cite

Nonsteroidal anti‐inflammatory drugs (NSAIDs) are among the most frequently used drugs that can cause liver toxicity. The aim of this study was to integrate bioanalytical and population pharmacokinetic (PopPK) assay to rapidly screen and quantify the concentrations of NSAIDs in plasma and monitor clinical safety. A liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the simultaneous quantification of acetaminophen (APAP), flurbiprofen (FLB), aspirin (ASP), and ibuprofen (IBP), four commonly used NSAIDs. The PopPK model of the signature toxicant was analyzed based on the published literature. The LC–MS/MS method was successfully validated and applied to determine NSAID concentrations in patient plasma samples. APAP, ASP, and IBP data were best fitted using a one‐compartment model, and FLB data were best fitted using a two‐compartment model. Bootstrapping and visual predictive checks suggested that a robust and reliable pharmacokinetic model was developed. A fast, simple, and sensitive LC–MS/MS method was developed and validated for determining APAP, FLB, ASP, and IBP in human plasma. Combined with the PopPK model, this method was applied to rapidly analyze the concentrations of NSAIDs in clinical samples from patients presenting to the emergency department with acute liver dysfunction and monitored NSAIDs clinical safety.

show abstract

Flurbiprofen

2014

Reactions Weekly

View full text Add to dashboard Cite

Prolonged Cholestatic Jaundice Associated With Flurbiprofen

Cited by 3 publications

References 10 publications

Drug-induced cholestasis: causative agents and challenges in diagnosis and management

Drug-induced cholestasis: causative agents and challenges in diagnosis and management

Rapid identification of potential nonsteroidal anti‐inflammatory drug overdose–induced liver toxicity and prediction of follow‐up exposure: Integrating bioanalytical and population pharmacokinetic assay

Flurbiprofen

Contact Info

Product

Resources

About